Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial

BACKGROUND: In metastatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil produce higher response rates and longer progression-free survival than do single agents. We aimed to compare overall survival in patients receiving combination treatment or interferon...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Gore, Martin E, Griffin, Clare L, Hancock, Barry, Patel, Poulam M, Pyle, Lynda, Aitchison, Michael, James, Nicholas, Oliver, Roderick TD, Mardiak, Jozef, Hussain, Tahera, Sylvester, Richard, Parmar, Mahesh KB, Royston, Patrick, Mulders, Peter FA
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2010
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2835851/
https://ncbi.nlm.nih.gov/pubmed/20153039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(09)61921-8
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia